Chongqing Zhifei Biological Products Co., Ltd. Stock

Equities

300122

CNE100000V20

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
34.22 CNY -0.70% Intraday chart for Chongqing Zhifei Biological Products Co., Ltd. -6.07% -44.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 58.19B 8.06B Sales 2025 * 64.49B 8.94B Capitalization 81.92B 11.35B
Net income 2024 * 10.27B 1.42B Net income 2025 * 12.44B 1.72B EV / Sales 2024 * 1.27 x
Net cash position 2024 * 7.86B 1.09B Net cash position 2025 * 14.74B 2.04B EV / Sales 2025 * 1.04 x
P/E ratio 2024 *
8.11 x
P/E ratio 2025 *
6.74 x
Employees 6,545
Yield 2024 *
2.71%
Yield 2025 *
2.95%
Free-Float 14.73%
More Fundamentals * Assessed data
Dynamic Chart
Chongqing Zhifei Biological Products' 2023 Profit Rises 7%; Shares Plunge 12% MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback Plan announced on February 22, 2024. CI
Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback announced on February 22, 2024, has closed with 6,210,253 shares, for CNY 300.01 million. CI
Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares. CI
Chongqing Zhifei Biological Products Co., Ltd. authorizes a Buyback Plan. CI
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments MT
Chongqing Zhifei Biological Products Co., Ltd. signed a letter of intent to acquire Shanghai Polaris Biology Co., Ltd. CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Middle East Conflict Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Monday MT
GSK Signs Distribution Deal With China's Zhifei for Shingles Vaccine MT
Chongqing Zhifei Biological Enters Exclusive Distribution Deal With GSK MT
Trending : GSK Signs $3 Billion Shingles Vaccine Deal in China DJ
GSK Strikes $3.06 Billion Shingles Vaccine Deal With China's Zhifei -- Update DJ
More news
1 day-0.70%
1 week-6.07%
Current month-2.51%
1 month-17.52%
3 months-33.42%
6 months-45.51%
Current year-44.00%
More quotes
1 week
34.17
Extreme 34.17
36.60
1 month
33.51
Extreme 33.51
42.44
Current year
33.51
Extreme 33.51
61.11
1 year
33.51
Extreme 33.51
70.27
3 years
33.51
Extreme 33.51
154.13
5 years
24.01
Extreme 24.0067
154.13
10 years
5.35
Extreme 5.35
154.13
More quotes
Managers TitleAgeSince
Chairman 43 13-12-31
Director of Finance/CFO 42 13-12-31
Chairman 71 09-08-16
Members of the board TitleAgeSince
Chairman 71 09-08-16
Director/Board Member 44 12-07-31
Corporate Officer/Principal 55 06-12-31
More insiders
Date Price Change Volume
24-05-16 34.22 -0.70% 14,649,700
24-05-15 34.46 -2.02% 13,058,680
24-05-14 35.17 +0.26% 14,786,970
24-05-13 35.08 -2.23% 20,047,860
24-05-10 35.88 -2.26% 22,887,320

End-of-day quote Shenzhen S.E., May 15, 2024

More quotes
Chongqing Zhifei Biological Products Co., Ltd. specializes in the research and development of vaccines for human use. The products include, in particular, bacterial vaccines for the prevention of meningitis, tuberculosis, rabies and influenza.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
34.22 CNY
Average target price
59.57 CNY
Spread / Average Target
+74.08%
Consensus
  1. Stock Market
  2. Equities
  3. 300122 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW